Loading
A phase 2 trial of MHB036C for Injection in advanced solid tumours, run by Minghui Pharmaceutical (Hangzhou) Ltd, now recruiting.
A Study of MHB036C Combined With MHB039A in Patients With Advanced Breast Cancer or Other Advanced Malignant Solid Tumors is a phase 2 interventional study registered as NCT07130383 by Minghui Pharmaceutical (Hangzhou) Ltd, with 210 participants planned, started 2025-09-30 and due to reach its primary completion in 2029-08. Interventions recorded: MHB036C for Injection and MHB039A for Injection.
Shares MHB036C, MHB039A, Minghui Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares MHB036C, Minghui Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares MHB039A, Minghui Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares MHB039A, Minghui Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Minghui Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Minghui Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Minghui Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Minghui Pharmaceutical and the tag pipeline.